BioFIT 2018

Published on 04/12/2018

4 – 5 December, 2018

Lille, France

ENYO Pharma’s CEO Jacky Vonderscher has been invited to speak in the conference programme of BioFIT 2018 in Lille, France, on December 4th and 5th. He had the opportunity to share his experience and knowledge during the following session – agnostic or pure players in the biotech sector: who is becoming prominent in the early-stage financing rounds? He was also able to give ENYO’s experience feedback following the first fundraising in 2016.

“BioFIT is the leading partnering event in Europe for technology transfer, academia-industry collaborations and early-stage innovations in the field of Life Sciences. BioFIT is also the marketplace for pre-seed, seed and Series A investment in Life Sciences. Over 1,200 attendees are expected this year as BioFIT 2017 was a record breaking edition, in particular in terms of the number of participants in the partnering with more than 2,700 scheduled one-to-one meetings, but above all, a very high satisfaction of the participants”. (www.biofit-event.com)

Read next in 'Events'

• The 2024 international workshop on Alport syndrome
• ENYO Pharma annonce un financement de Série C de 39 millions d'euros et l’autorisation de la FDA (IND) pour tester Vonafexor dans un essai clinique de Phase 2 pour les patients atteints du syndrome d'Alport
• 6th CKD Summit – Chronic Kidney Disease Drug Development
• ASN Kidney Week
• Alport Connect 2023, the annual Alport syndrome patient and family meeting in US